You are here
Biotricity Expands Salesforce to Cover Key US Markets and Begins Advisory Board Expansion to Move Into Preemptive Heart Disease Diagnostics
The Company has Expanded its Sales Team to Cover Two Additional Geographic Centers in the US
REDWOOD CITY, Calif., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB: BTCY), a medical diagnostic and consumer healthcare technology company, has expanded its sales team to cover two additional geographic centers in the US that are key to driving faster adoption of its flagship product, Bioflux. The Company has been experiencing great traction with its technology in the marketplace and feels this is the right time to capitalize on its initial momentum and increase its regional footprint. Biotricity is confident that broadening its influence through expansion in high growth sectors will help accelerate sales, drive revenue, and develop market share.
The Company is also expanding its Scientific Advisory board with a focus on tailoring its solution for preemptive heart disease identification in new markets. The focus of healthcare is shifting towards outpatient healthcare, with prevention at the forefront of the movement. Remote patient monitoring can become a key driver of this shift when implemented in the right markets. “Our Bioflux has proven to be a formidable technology as we continue to gain significant clinical approval and adoption in emerging markets of outpatient monitoring, which also coincides with CMS’s ongoing strategies and efforts to transition many surgical and endovascular procedures to Ambulatory Surgery Centers,” said Casey Shattuck, VP of Sales. “We truly believe we are entering the infancy of outpatient monitoring.” Biotricity has already identified three potential markets where its technology can be applied and plans to announce more details on this initiative over the next three quarters.
“One of the greatest challenges facing the United States today is the growing cost of healthcare for chronic diseases such as heart disease,” said Waqaas Al-Siddiq, Biotricity Founder and CEO. “Preemptive diagnostics through remote monitoring has the potential to make a major impact on this issue, driving a reduction in costs and improved patient outcomes and quality of life.” The Company considers remote monitoring medical-grade devices a significant component of its product development roadmap and plans to expand its offering with time.
For more news, or to follow our publications, please visit https://www.biotricity.com/newsroom/
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement. Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “should,” “would,” “will,” “could,” “scheduled,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” “seek,” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of Bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.